1 |
Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fer- tilisation using buserelin and gonadotropins. Lancet 1984; ii: 1284-5
|
2 |
Olivennes F, Alvarez S, Fanchin R, Bouchard P, Salat-Baroux J, Frydman R. Plasmatic and follicular fluid levels of a new GnRH antagonist (Cetrorelix) used in IVF patients with a simple single admini- stration protocol in the late follicular phase in stimu- lated and spontaneous cycles. Fertil Steril 1997; 68: 47
|
3 |
Albano C, Felberbaum R, Smitz J. On behalf of European Cetrorelix study group. Ovarian hypersti- mulation with HMG: result of a prospective rando- mized phase III European study comparing the lute- inizing hormon released hormon (LHRH)-antago- nist cetrorelix and the LHRH-agonist buscrelin. Hum REport 2003; 3: 526-31
|
4 |
Lashen H. Investigations for infertility Current Obstetric Gynaecol 2004; 14(4): 269-76
|
5 |
Ragni G, Maggioni P, Guermandi E, Testa A, Baroni E, Colombo M, et al. Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles. Fertil Steril 1999; 72: 619-22
DOI
ScienceOn
|
6 |
Diamond MP, Hill GA, Webster BW, Herbert CM, Rogers BJ, Osteen KG, et al. Comparison of human menopausal gonadotropin, clomiphen citrate, and combined human menopausal gonadotropin-clomi- phen citrate stimulation protocols for in vitro fer- tilization. Fertil Steril 1986; 46: 1108-12
PUBMED
|
7 |
Diedrich K, Diedrich C, Santos E, Zoll C, Al-Han- sani S, Reissmann T, et al. Suppression of the endo- genous luteinizing hormonesurge by the gonado- tropin-release hormone agonist cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-91
PUBMED
|
8 |
Diedrich K, Diedrich C, Santos E. Suppression of the endogeneous luteinizing hormon surge by the gonadotropin-releasing hormon antagonist Cetrorelix during ovarian stimulation. Hum Report 1994; 9: 788-91
DOI
|
9 |
Random MX, Blotner MB, Bohrer M, Corsan G, Kemmann B. Does increasing frequency of intrau- terine insemination improve pregnancy rate signifi- cantly during superovulation cycles? Fertil Steril 1994; 61: 303-7
|
10 |
Saeed Alborzi, S. Motazedian, S. Jannati. Compa- rison of the effectiveness of single IUI versus dou- ble IUI Fertil Steril 2003; 80: 595-9
|
11 |
Dickey RP, Pyrzak R, Lu PY, Taylor SN, Rye PH. Comparison of sperm quality necessary for succe- ssful intrauterine insemination with World Health Organization threshold values for normal sperm. Fertil Steril 1999; 71: 684-9
DOI
ScienceOn
|
12 |
Chaffkin LM, Nulsen JC, Lucian AA, Metzger DA. A comparrative analysis of the cycle fecundity rates associated with combine human menopausal gona- dotropine and intrauterine insermination versus either HMG or intrauterine insermination alone. Fertil Steril 1991; 55: 252-7
DOI
PUBMED
|
13 |
Elchalal U, Schenken JG. The pathophysiology of ovarian hyperstimulation syndrom -view and idea. Hum Report 1997; 12:1129-31
DOI
ScienceOn
|
14 |
Michael M, Brian M. Berger. High dose Follicle Sti- mulating Hormone (FSH) and Human Menopausal Gonadotropin (HMG) combined with a single dose of Cetrorelix: can it normalize the response of the poor responder? Fertility and Sterility 2003; 80: 191
|
15 |
Silverberg KM, Johnson JV, Olive DL, burns W, Schenken RS. A prospective, randomized trial com- paring two different intrauterine insemination regi- mens in controlled ovarian hyperstimulation cycles. Fertil Steril 1992; 57: 357-61
DOI
PUBMED
|
16 |
Hughes EG, Fedorkow DM, Daya S, Sagle MA, VAn de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gameta infrafallopian transfer: a meta analysis of randomized controlled trials. Fertil Steril 1992; 58(5): 888-96
DOI
PUBMED
|
17 |
Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hy- perstimulation. Fertil Steril 1997; 5: 917-22
|